Articles

The future of PRRT lies in its use in combination therapies, including PRRT with chemotherapy, immunotherapy, and as neoadjuvant/adjuvant therapy with surgery. Read More ›

Targeted alpha-particle therapy is in development for targeted radionuclide therapy of NETs, employing alpha decay to treat diseased tissue at close proximity. Read More ›

Telotristat ethyl is safe and effective in reducing intractable diarrhea in patients with carcinoid syndrome. Read More ›

An expert working group developed specific ideas for future research programs in NETs, as well as ways to improve access to NET clinical trials. Read More ›

The combination of brentuximab vedotin and ibrutinib was well-tolerated and resulted in an overall response rate of 69%, a complete response rate of 46%, and a disease control rate of 100% in patients with relapsed/refractory Hodgkin lymphoma. Read More ›

The preliminary results of a multicenter phase 1b dose-escalation study evaluated the safety, tolerability, and efficacy of 2 novel venetoclax-based combination therapies, in combination with the MEK inhibitor cobimetinib or the MDM2 inhibitor idasanutlin, in relapsed/refractory (R/R) acute myeloid leukemia (AML). Read More ›

In a cost-effectiveness and cost-utility analysis of ibrutinib versus allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with relapsed/refractory CLL with del(17p), ibrutinib provides significantly greater clinical and economic value over the first 3 years of treatment, but the benefit declines beyond 3 years. Read More ›

Interim results of an ongoing phase 1 study showed that the addition of the selective FLT3 inhibitor quizartinib to azacitidine or low-dose cytarabine produced high overall response rates in patients with FLT3-ITD–mutated myeloid leukemias. Read More ›

The combination of ibrutinib plus nivolumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma was safe but not more effective than ibrutinib alone. It did, however, demonstrate superior efficacy in patients with Richter’s transformation, although the study did not select patients with elevated PD-L1 levels. Read More ›

Ivosidenib monotherapy is well-tolerated and produced durable remissions in high-risk patients with relapsed/refractory acute myeloid leukemia (AML). Read More ›